Show simple item record

dc.contributor.authorRamírez Carracedo, Rafael
dc.contributor.authorTesoro, Laura
dc.contributor.authorHernández, Ignacio
dc.contributor.authorDíez Mata, Javier
dc.contributor.authorPiñeiro, David
dc.contributor.authorHernández Jiménez, Macarena
dc.contributor.authorZamorano, José Luis
dc.contributor.authorZaragoza Sánchez, Carlos 
dc.date.accessioned2020-09-11T09:34:09Z
dc.date.available2020-09-11T09:34:09Z
dc.date.issued2020
dc.identifier.issn2218-273Xspa
dc.identifier.urihttp://hdl.handle.net/10641/1964
dc.description.abstractToll-like receptor 4 (TLR4) contributes to the pathogenesis of coronary ischemia/reperfusion (IR). To test whether the new TLR4 antagonist, ApTOLL, may prevent coronary IR damage, we administered 0.078 mg/kg ApTOLL or Placebo in pigs subjected to IR, analyzing the levels of cardiac troponins, matrix metalloproteinases, pro-, and anti-inflammatory cytokines, heart function, and tissue integrity over a period of 7 days after IR. Our results show that ApTOLL reduced cardiac troponin-1 24 h after administration, improving heart function, as detected by a significant recovery of the left ventricle ejection fraction (LVEF) and the shortening fraction (FS) cardiac parameters. The extension of necrotic and fibrotic areas was also reduced, as detected by Evans blue/2,3,5-triphenyltetrazolium chloride (TTC) staining, Hematoxylin/Eosine, and Masson Trichrome staining of heart sections, together with a significant reduction in the expression of the extracellular matrix-degrading, matrix metalloproteinase 9. Finally, the expression of the following cytokines, CCL1, CCL2, MIP1-A-B, CCL5, CD40L, C5/C5A, CXCL1, CXCL10, CXCL11, CXCL12, G-CSF, GM-CSF, ICAM-1, INF-g, IL1-a, ILI-b, IL-1Ra, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL16, IL17-A, IL17- E, IL18, IL21, IL27, IL32, MIF, SERPIN-E1, TNF-a, and TREM-1, were also assayed, detecting a pronounced decrease of pro-inflammatory cytokines after 7 days of treatment with ApTOLL. Altogether, our results show that ApTOLL is a promising new tool for the treatment of acute myocardial infarction (AMI).spa
dc.language.isoengspa
dc.publisherBiomoleculesspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectToll-like receptor 4spa
dc.subjectAcutemyocardial infarctionspa
dc.subjectCytokinesspa
dc.subjectMatrixmetalloproteinasesspa
dc.titleTargeting TLR4 with ApTOLL Improves Heart Function in Response to Coronary Ischemia Reperfusion in Pigs Undergoing Acute Myocardial Infarction.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent3782 KBspa
dc.identifier.doi10.3390/biom10081167spa
dc.relation.publisherversionhttps://www.mdpi.com/2218-273X/10/8/1167spa


Files in this item

FilesSizeFormatView
1.- Targeting TLR4 with ApTOLL.pdf3.692MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España